CREATICS LLC

Capabilities

Creatics is on the forefront of early-stage cancer diagnosis via the collection and analysis of non-invasive liquid biopsies. We’ve recently discovered a limited biomarker panel capable of accurately diagnosing individuals with early-stage Pancreatic cancer; a condition that is normally asymptomatic until late-stage disease. The ability to diagnose this deadly cancer prior to metastasis is critical, however there are currently no non-invasive diagnostic methods available to oncologists. Creatics is working through Phase-1 clinical studies with the end goal of making this highly accurate diagnostic available to patients worldwide.